NCT07536100 VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia
| NCT ID | NCT07536100 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institute of Dermatology, Thailand |
| Condition | Androgenetic Alopecia (AGA) |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-05-05 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2026-05-05 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the effectiveness and tolerability of a peptide-based hair serum compared with topical minoxidil in patients with androgenetic alopecia. Participants will be randomly assigned, in a double-blind manner, to receive either the peptide hair serum or topical minoxidil. The primary objective is to assess improvement in hair growth over the study period, including changes in hair density and hair thickness. Secondary outcomes will include safety and tolerability assessments. The findings of this study may provide evidence supporting an alternative treatment option for patients with androgenetic alopecia.
Eligibility Criteria
Inclusion Criteria: * Male or female participants aged ≥18 years. * Diagnosed with androgenetic alopecia (AGA): Norwood-Hamilton classification III-V in males or Ludwig classification I-II in females. * Able to read and write for completion of study questionnaires (e.g., Patient Global Assessment, Hair Growth Questionnaire). * Willing to comply with study procedures, including maintaining consistent hair color and hairstyle throughout the study. * Hair length in the non-balding area (vertex surrounding area) ≥2 cm at each visit. * Able to attend all scheduled visits during the 24-week study period. Exclusion Criteria: * Presence of unstable or uncontrolled systemic diseases that may affect hair growth or loss within 6 months prior to screening (e.g., liver, renal, thyroid, cardiovascular, neurological diseases, diabetes, anemia). * History of malignancy within the past 5 years, except adequately treated basal cell carcinoma or squamous cell carcinoma. * Psychiatric disorders or other conditions that may affect participant safety or compliance. * Pregnant or breastfeeding women. Hair and scalp-related exclusions: * Diffuse hair thinning involving the occipital area. * Scalp conditions or diseases affecting hair growth (e.g., tinea infection, non-AGA hair loss, psoriasis, uncontrolled seborrheic dermatitis). * History of hair transplantation at any time or hair extensions within 6 months prior to screening. * Use of cosmetic products for hair loss concealment within 2 weeks prior to screening. * Use of light/laser therapy on the scalp within 3 months prior to screening. * Use of supplements related to hair growth (e.g., zinc, biotin) within 3 months prior to screening. * Use of hair products containing active ingredients (e.g., caffeine, peptides) within 3 months prior to screening. * Hair procedures such as mesotherapy or stem cell injection within 3 months prior to screening. Medication-related exclusions: * Known hypersensitivity to study-related products or ingredients. * Use of dutasteride within 12 months prior to screening. * Use of systemic cytotoxic agents. * Use of systemic glucocorticoids within 3 months prior to screening (except inhaled or topical corticosteroids not applied to the scalp). * Use within 6 months prior to screening of: * Minoxidil (topical or oral) * Finasteride (topical or oral) * Anti-androgenic drugs (e.g., spironolactone, cyproterone acetate, flutamide, bicalutamide) * Prostaglandin analogs applied to the scalp * Estrogen or progesterone topical preparations * Tamoxifen * Drugs associated with hypertrichosis (e.g., cyclosporine, phenytoin) * Drugs associated with hair loss (e.g., valproic acid) * Participation in another clinical trial within 1 month prior to screening or during this study.
Contact & Investigator
Chinmanat Lekhavat, MD, PhD
PRINCIPAL INVESTIGATOR
Institute of Dermatology
Frequently Asked Questions
Who can join the NCT07536100 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Androgenetic Alopecia (AGA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07536100 currently recruiting?
Yes, NCT07536100 is actively recruiting participants. Contact the research team at chinmanat@inderm.org for enrollment information.
Where is the NCT07536100 trial being conducted?
This trial is being conducted at Bangkok, Thailand, Bangkok, Thailand.
Who is sponsoring the NCT07536100 clinical trial?
NCT07536100 is sponsored by Institute of Dermatology, Thailand. The principal investigator is Chinmanat Lekhavat, MD, PhD at Institute of Dermatology. The trial plans to enroll 80 participants.